Europe and Middle East & Africa Meningitis Diagnostic Testing Market Outlook 2031

  • The EMEA meningitis diagnostic testing market was valued over US$ 55.95 Mn in 2020
  • It is estimated to expand at a CAGR of 3.7% from 2021 to 2031
  • The EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by the end of 2031

Analysts’ Viewpoint on Europe and Middle East & Africa Meningitis Diagnostic Testing Market

Companies in the EMEA meningitis diagnostic testing market are taking advantage of governments’ stimulus packages to stay financially afloat during the ongoing COVID-19 pandemic. Currently available rapid diagnostics tests (RDTs) to detect meningococcal meningitis are found to have a short shelf life. Hence, companies in the EMEA meningitis diagnostic testing market are increasing research to develop RDTs with good sensitivities and specificities. Rapid, accurate, and specific identification of the causative organism are necessary to ensure an effective public health response. Apart from diagnostic tests, healthcare companies are diversifying in the implementation of conjugate polysaccharide vaccines to revolutionize public health management.

New Kits Hold Potentials to Improve Molecular Diagnosis of Bacterial Meningitis

The technology of diagnostic kit for bacterial meningitis using real-time HRM PCR holds potential to improve clinical numbers. Companies in the EMEA meningitis diagnostic testing market should collaborate with researchers to develop new kits that help to cut down costs of molecular diagnosis of bacterial meningitis. Stakeholders are taking efforts to increase the availability of these kits amongst the common public and mainly at private laboratories.

Companies in the EMEA meningitis diagnostic testing market are increasing R&D in developing kits that make use of a single fluorophore to detect the target genes through melting temperature analysis of the bacterial target gene. It has been found that each gene detected has a different melting temperature, easily visualized in a graph at the end of the amplification.

Request a sample to get extensive insights into the Meningitis Diagnostic Testing Market

Early Diagnosis of COVID-19 and Meningitis to Prevent Disease Spread

Common symptoms of COVID-19 and meningitis are creating concerns for both healthcare providers and the general public. Thus, robust diagnostic testing has become the need of the hour during the ongoing pandemic. Stakeholders in the EMEA meningitis diagnostic testing market are increasing the availability of products to meet healthcare needs of individuals.

In order to reduce stress on healthcare facilities, stakeholders in the EMEA meningitis diagnostic testing market are increasing awareness and facilitating early diagnosis to prevent the spread of diseases. They are maintaining optimum inventory levels to ensure continuity in supply chains. Companies are rethinking their manufacturing activities since financial situations have been squeezed for many. They are taking data-driven decisions to sustain volatile market sentiments.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Logistical Challenges in Africa Affect Clinical Numbers for Meningitis Diagnostic Testing

Transporting samples to laboratories have many logistical challenges in countries falling under the meningitis belt in Africa, as latex agglutination requires refrigeration and lab equipment. Moreover, this technique is dependent on a sample of spinal fluid from the patient taken by lumber puncture.

Participants in the market should collaborate with clinicians, medical practitioners, and labs to invest in training of medical staff or hire trained staff in primary healthcare settings and remote areas.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Meningitis Diagnostic Testing Market 

Molecular Diagnostic Assays Help Distinguish Between Different Bacteria

Bacterial meningitis is becoming one of the major causes of morbidity and mortality. Participants in the EMEA meningitis diagnostic testing market are taking advantage of this opportunity to enable rapid identification of the aetiological agent of meningitis. Such innovations are benefitting healthcare providers participating in clinical and public health management.

Since microbiological culture is complex, slow, and often impacted by prior antimicrobial treatment of the patient, companies in the EMEA meningitis diagnostic testing market are increasing the availability of molecular diagnostic assays for bacterial detection. Distinguishing between meningitis caused by meningococcus, pneumococcus, and others is becoming an important aspect of detection techniques.

PCR Tests Support Rapid Outbreak Detection in Africa

Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market. Companies are offering new lateral flow tests for the diagnosis of Neisseria meningitides, MeningoSpeed, and other bacteria to support rapid outbreak detection in Africa. The microbial diagnosis of meningitis is currently based on culture or more frequently on polymerase chain reaction (PCR) tests carried out by national reference laboratories (NRLs) on a sample of cerebrospinal fluid (CSF).

PCR tests require the maintaining of sample in a cold chain in primary health care centers (PHCs) and during transportation to the NRL. However, this makes the early identification of circulating strains difficult. In order to reduce the time needed to detect circulating strains, healthcare companies are developing diagnostic tests that can be used at bedside.

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market: Overview

  • Meningitis is an infection of the protective membranes that surround the brain and spinal cord. It can affect anyone, but is most common in babies, young children, teenagers, and young adults. Symptoms include fever, headache, stiff neck, seizures, and others. The various types of meningitis are viral meningitis, bacterial meningitis, and fungal meningitis.
  • Latex agglutination test is a passive agglutination test, wherein analytes (antigens) are adsorbed onto latex particles. The test has a range of specificity and sensitivity, ranging from 60% to 93% for various microorganisms (such as Streptococcus pneumonia, Hemophilus influenzae, and Neisseria meningitidis).
  • Lateral flow assay is also known as immunochromatographic test or dipstick assay. It is a paper-based test to detect analytes (antigens) in a complex mixture, wherein the sample to be analyzed is placed on a device and results are displayed within five to 30 minutes. These tests are widely used as point-of-care testing.

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market: Key Drivers

  • Rise in demand for point-of-care services is anticipated to drive the meningitis diagnostic testing market in EMEA during the forecast period. Point-of-care services provide more accurate results in less time compared to traditional methods.
  • New, innovative technologies such PCR and next-generation sequencing are available in the market, providing a less expensive way for the diagnosis, prognosis, and therapy selection in patients during their treatment. This helps physicians frame appropriate therapeutic systems for patients suffering from the infectious disease.
  • In May 2018, BioGX B.V. launched Six CE-Mark tests for meningitis and antibiotic resistance. Meningitis test includes viral meningitis HSV/VZV, bacterial meningitis NSH, and bacterial meningitis ELGBS.

Market Segmentation: Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

  • In terms of product type, the meningitis diagnostic testing market in EMEA has been classified into latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and others
  • Based on panel type, the meningitis diagnostic testing market in EMEA has been bifurcated into syndromic full multiplex panel and low plex panel
  • In terms of end-user, the meningitis diagnostic testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The meningitis diagnostic testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

  • Europe dominated the meningitis diagnostic testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in expenditure on healthcare infrastructure, and surge in demand for better healthcare facilities fuel the growth of the market in Europe.
  • Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. Growth of the market in Germany can be attributed to increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies.

Major Players

  • The meningitis diagnostic testing market report concludes with the company profiles section, which includes key information about major players in the meningitis diagnostic testing market in EMEA
  • Leading players analyzed in the report include
    • Thermo Fisher Scientific, Inc.
    • Abbott Laboratories
    • BioFire Diagnostics
    • Bio-Rad Laboratories, Inc.
    • ELITechGroup
    • Fast Track Diagnostics Ltd. (Siemens Healthineers)
    • IMMY
    • Nanosphere (Luminex Corporation)
    • Qnostics
    • Seegene, Inc.
  • Each of these players has been profiled in the meningitis diagnostic testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 55.95 Mn

Market Forecast Value in 2031

US$ 83.51 Mn

Growth Rate (CAGR)

3.7%

Forecast Period

2021–2031

Historical Data Available for

2017–2019

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Latex Agglutination Tests
    • Lateral Flow Assay
    • PCR Assay
    • ELISA Tests
    • Culture Test
    • Others
  • Panel Type
    • Syndromic Full Multiplex Panel
    • Low Plex Panel
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Finland
  • Austria
  • Switzerland
  • Benelux
  • Norway
  • Poland
  • Rest of Europe
  • GCC Countries
  • South Africa
  • Rest of Middle east & Africa

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • BioFire Diagnostics
  • Bio-Rad Laboratories, Inc.
  • ELITechGroup
  • Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
  • IMMY
  • Nanosphere (Luminex Corporation)
  • Qnostics
  • Seegene, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Scope of Report

TMR’s report on the meningitis diagnostic testing market in EMEA studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the meningitis diagnostic testing market in EMEA for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the meningitis diagnostic testing market in EMEA from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the meningitis diagnostic testing market in EMEA.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the meningitis diagnostic testing market in EMEA.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the meningitis diagnostic testing market in EMEA. These serve as valuable tools for existing market players as well as for entities interested in participating in the meningitis diagnostic testing market in EMEA.

The report delves into the competition landscape of the meningitis diagnostic testing market in EMEA. Key players operating in the meningitis diagnostic testing market in EMEA have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the meningitis diagnostic testing market in EMEA profiled in this report.

Key Questions Answered in Europe and Middle East & Africa Meningitis diagnostic testing Market Report

  • What is the sales/revenue generated by meningitis diagnostic testing across all regions during the forecast period?
  • What are the opportunities in the meningitis diagnostic testing market in EMEA?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue in EMEA market in 2031?
  • Which segment is likely to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in EMEA market?

Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Research Objectives and Research Approach

The comprehensive report on the meningitis diagnostic testing market in EMEA begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments are visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the meningitis diagnostic testing market in EMEA in terms of product type, panel type, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the meningitis diagnostic testing market in EMEA.

Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Segmentation

TMR’s study on the meningitis diagnostic testing market in EMEA includes information divided into four segments: product type, panel type, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the meningitis diagnostic testing market in EMEA are discussed in detail.

Product Type
  • Latex Agglutination Tests
  • Lateral Flow Assay
  • PCR Assay
  • ELISA Tests
  • Culture Test
  • Others
Panel Type
  • Syndromic Full Multiplex Panel
  • Low Plex Panel
End-user
  • Hospitals
  • Diagnostic Centers
  • Others
Region
  • Europe
  • Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Success Factors for Top Players

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)

    5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)

    5.4. Regulatory Scenario

6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, By Product, 2017–2031

        6.3.1. Latex Agglutination Tests

        6.3.2. Lateral Flow Assay

        6.3.3. PCR Assay

        6.3.4. ELISA Tests

        6.3.5. Culture Test

        6.3.6. Others

    6.4. Market Attractiveness Analysis, By Product

7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Type, 2017–2031

        7.3.1. Syndromic Full Multiplex Panel

        7.3.2. Low Plex Panel

    7.4. Market Attractiveness Analysis, By Type

8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, By End-user, 2017–2031

    8.4. Market Attractiveness Analysis, By End-user

9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region

    9.1. Key Findings

    9.2. Market Value Forecast, By Region

10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, By Product, 2017–2031

        10.2.1. Latex Agglutination Tests

        10.2.2. Lateral Flow Assay

        10.2.3. PCR Assay

        10.2.4. ELISA Tests

        10.2.5. Culture Test

        10.2.6. Others

    10.3. Market Value Forecast, By Type, 2017–2031

        10.3.1. Syndromic Full Multiplex Panel

        10.3.2. Low Plex Panel

    10.4. Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospitals

        10.4.2. Diagnostic Centers

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. Germany

            10.5.1.1. Market Value Forecast, by Product, 2017–2031

                10.5.1.1.1. Latex Agglutination Tests

                10.5.1.1.2. Lateral Flow Assay

                10.5.1.1.3. PCR Assay

                10.5.1.1.4. ELISA Tests

                10.5.1.1.5. Culture Test

                10.5.1.1.6. Others

            10.5.1.2. Market Value Forecast, by Type, 2017–2031

                10.5.1.2.1. Syndromic Full Multiplex Panel

                10.5.1.2.2. Low Plex Panel

            10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                10.5.1.3.1. Hospitals

                10.5.1.3.2. Diagnostic Centers

                10.5.1.3.3. Others

        10.5.2. U.K.

            10.5.2.1. Market Value Forecast, by Product, 2017–2031

                10.5.2.1.1. Latex Agglutination Tests

                10.5.2.1.2. Lateral Flow Assay

                10.5.2.1.3. PCR Assay

                10.5.2.1.4. ELISA Tests

                10.5.2.1.5. Culture Test

                10.5.2.1.6. Others

            10.5.2.2. Market Value Forecast, by Type, 2017–2031

                10.5.2.2.1. Syndromic Full Multiplex Panel

                10.5.2.2.2. Low Plex Panel

            10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                10.5.2.3.1. Hospitals

                10.5.2.3.2. Diagnostic Centers

                10.5.2.3.3. Others

        10.5.3. France

            10.5.3.1. Market Value Forecast, by Product, 2017–2031

                10.5.3.1.1. Latex Agglutination Tests

                10.5.3.1.2. Lateral Flow Assay

                10.5.3.1.3. PCR Assay

                10.5.3.1.4. ELISA Tests

                10.5.3.1.5. Culture Test

                10.5.3.1.6. Others

            10.5.3.2. Market Value Forecast, by Type, 2017–2031

                10.5.3.2.1. Syndromic Full Multiplex Panel

                10.5.3.2.2. Low Plex Panel

            10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                10.5.3.3.1. Hospitals

                10.5.3.3.2. Diagnostic Centers

                10.5.3.3.3. Others

        10.5.4. Italy

            10.5.4.1. Market Value Forecast, by Product, 2017–2031

                10.5.4.1.1. Latex Agglutination Tests

                10.5.4.1.2. Lateral Flow Assay

                10.5.4.1.3. PCR Assay

                10.5.4.1.4. ELISA Tests

                10.5.4.1.5. Culture Test

                10.5.4.1.6. Others

            10.5.4.2. Market Value Forecast, by Type, 2017–2031

                10.5.4.2.1. Syndromic Full Multiplex Panel

                10.5.4.2.2. Low Plex Panel

            10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                10.5.4.3.1. Hospitals

                10.5.4.3.2. Diagnostic Centers

                10.5.4.3.3. Others

        10.5.5. Spain

            10.5.5.1. Market Value Forecast, by Product, 2017–2031

                10.5.5.1.1. Latex Agglutination Tests

                10.5.5.1.2. Lateral Flow Assay

                10.5.5.1.3. PCR Assay

                10.5.5.1.4. ELISA Tests

                10.5.5.1.5. Culture Test

                10.5.5.1.6. Others

            10.5.5.2. Market Value Forecast, by Type, 2017–2031

                10.5.5.2.1. Syndromic Full Multiplex Panel

                10.5.5.2.2. Low Plex Panel

            10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                10.5.5.3.1. Hospitals

                10.5.5.3.2. Diagnostic Centers

                10.5.5.3.3. Others

        10.5.6. Benelux

            10.5.6.1. Market Value Forecast, by Product, 2017–2031

                10.5.6.1.1. Latex Agglutination Tests

                10.5.6.1.2. Lateral Flow Assay

                10.5.6.1.3. PCR Assay

                10.5.6.1.4. ELISA Tests

                10.5.6.1.5. Culture Test

                10.5.6.1.6. Others

            10.5.6.2. Market Value Forecast, by Type, 2017–2031

                10.5.6.2.1. Syndromic Full Multiplex Panel

                10.5.6.2.2. Low Plex Panel

            10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                10.5.6.3.1. Hospitals

                10.5.6.3.2. Diagnostic Centers

                10.5.6.3.3. Others

        10.5.7. Poland

            10.5.7.1. Market Value Forecast, by Product, 2017–2031

                10.5.7.1.1. Latex Agglutination Tests

                10.5.7.1.2. Lateral Flow Assay

                10.5.7.1.3. PCR Assay

                10.5.7.1.4. ELISA Tests

                10.5.7.1.5. Culture Test

                10.5.7.1.6. Others

            10.5.7.2. Market Value Forecast, by Type, 2017–2031

                10.5.7.2.1. Syndromic Full Multiplex Panel

                10.5.7.2.2. Low Plex Panel

            10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                10.5.7.3.1. Hospitals

                10.5.7.3.2. Diagnostic Centers

                10.5.7.3.3. Others

        10.5.8. Norway

            10.5.8.1. Market Value Forecast, by Product, 2017–2031

                10.5.8.1.1. Latex Agglutination Tests

                10.5.8.1.2. Lateral Flow Assay

                10.5.8.1.3. PCR Assay

                10.5.8.1.4. ELISA Tests

                10.5.8.1.5. Culture Test

                10.5.8.1.6. Others

            10.5.8.2. Market Value Forecast, by Type, 2017–2031

                10.5.8.2.1. Syndromic Full Multiplex Panel

                10.5.8.2.2. Low Plex Panel

            10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                10.5.8.3.1. Hospitals

                10.5.8.3.2. Diagnostic Centers

                10.5.8.3.3. Others

        10.5.9. Sweden

            10.5.9.1. Market Value Forecast, by Product, 2017–2031

                10.5.9.1.1. Latex Agglutination Tests

                10.5.9.1.2. Lateral Flow Assay

                10.5.9.1.3. PCR Assay

                10.5.9.1.4. ELISA Tests

                10.5.9.1.5. Culture Test

                10.5.9.1.6. Others

            10.5.9.2. Market Value Forecast, by Type, 2017–2031

                10.5.9.2.1. Syndromic Full Multiplex Panel

                10.5.9.2.2. Low Plex Panel

            10.5.9.3. Market Value Forecast, by End-user, 2017-2031

                10.5.9.3.1. Hospitals

                10.5.9.3.2. Diagnostic Centers

                10.5.9.3.3. Others

        10.5.10. Denmark

            10.5.10.1. Market Value Forecast, by Product, 2017–2031

                10.5.10.1.1. Latex Agglutination Tests

                10.5.10.1.2. Lateral Flow Assay

                10.5.10.1.3. PCR Assay

                10.5.10.1.4. ELISA Tests

                10.5.10.1.5. Culture Test

                10.5.10.1.6. Others

            10.5.10.2. Market Value Forecast, by Type, 2017–2031

                10.5.10.2.1. Syndromic Full Multiplex Panel

                10.5.10.2.2. Low Plex Panel

            10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                10.5.10.3.1. Hospitals

                10.5.10.3.2. Diagnostic Centers

                10.5.10.3.3. Others

        10.5.11. Finland

            10.5.11.1. Market Value Forecast, by Product, 2017–2031

                10.5.11.1.1. Latex Agglutination Tests

                10.5.11.1.2. Lateral Flow Assay

                10.5.11.1.3. PCR Assay

                10.5.11.1.4. ELISA Tests

                10.5.11.1.5. Culture Test

                10.5.11.1.6. Others

            10.5.11.2. Market Value Forecast, by Type, 2017–2031

                10.5.11.2.1. Syndromic Full Multiplex Panel

                10.5.11.2.2. Low Plex Panel

            10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                10.5.11.3.1. Hospitals

                10.5.11.3.2. Diagnostic Centers

                10.5.11.3.3. Others

        10.5.12. Austria

            10.5.12.1. Market Value Forecast, by Product, 2017–2031

                10.5.12.1.1. Latex Agglutination Tests

                10.5.12.1.2. Lateral Flow Assay

                10.5.12.1.3. PCR Assay

                10.5.12.1.4. ELISA Tests

                10.5.12.1.5. Culture Test

                10.5.12.1.6. Others

            10.5.12.2. Market Value Forecast, by Type, 2017–2031

                10.5.12.2.1. Syndromic Full Multiplex Panel

                10.5.12.2.2. Low Plex Panel

            10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                10.5.12.3.1. Hospitals

                10.5.12.3.2. Diagnostic Centers

                10.5.12.3.3. Others

        10.5.13. Switzerland

            10.5.13.1. Market Value Forecast, by Product, 2017–2031

                10.5.13.1.1. Latex Agglutination Tests

                10.5.13.1.2. Lateral Flow Assay

                10.5.13.1.3. PCR Assay

                10.5.13.1.4. ELISA Tests

                10.5.13.1.5. Culture Test

                10.5.13.1.6. Others

            10.5.13.2. Market Value Forecast, by Type, 2017–2031

                10.5.13.2.1. Syndromic Full Multiplex Panel

                10.5.13.2.2. Low Plex Panel

            10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                10.5.13.3.1. Hospitals

                10.5.13.3.2. Diagnostic Centers

                10.5.13.3.3. Others

        10.5.14. Rest of Europe

            10.5.14.1. Market Value Forecast, by Product, 2017–2031

                10.5.14.1.1. Latex Agglutination Tests

                10.5.14.1.2. Lateral Flow Assay

                10.5.14.1.3. PCR Assay

                10.5.14.1.4. ELISA Tests

                10.5.14.1.5. Culture Test

                10.5.14.1.6. Others

            10.5.14.2. Market Value Forecast, by Type, 2017–2031

                10.5.14.2.1. Syndromic Full Multiplex Panel

                10.5.14.2.2. Low Plex Panel

            10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                10.5.14.3.1. Hospitals

                10.5.14.3.2. Diagnostic Centers

                10.5.14.3.3. Others

    10.6. Market Attractiveness Analysis

        10.6.1. By Product

        10.6.2. By Type

        10.6.3. By End-user

        10.6.4. By Country

11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2017–2031

        11.2.1. Latex Agglutination Tests

        11.2.2. Lateral Flow Assay

        11.2.3. PCR Assay

        11.2.4. ELISA Tests

        11.2.5. Culture Test

        11.2.6. Others

    11.3. Market Value Forecast, by Type, 2017–2031

        11.3.1. Syndromic Full Multiplex Panel

        11.3.2. Low Plex Panel

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospitals

        11.4.2. Diagnostic Centers

        11.4.3. Others

    11.5. Market Value Forecast, by Country, 2017–2031

        11.5.1. GCC Countries

            11.5.1.1. Market Value Forecast, by Product, 2017–2031

                11.5.1.1.1. Latex Agglutination Tests

                11.5.1.1.2. Lateral Flow Assay

                11.5.1.1.3. PCR Assay

                11.5.1.1.4. ELISA Tests

                11.5.1.1.5. Culture Test

                11.5.1.1.6. Others

            11.5.1.2. Market Value Forecast, by Type, 2017–2031

                11.5.1.2.1. Syndromic Full Multiplex Panel

                11.5.1.2.2. Low Plex Panel

            11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                11.5.1.3.1. Hospitals

                11.5.1.3.2. Diagnostic Centers

                11.5.1.3.3. Others

        11.5.2. South Africa

            11.5.2.1. Market Value Forecast, by Product, 2017–2031

                11.5.2.1.1. Latex Agglutination Tests

                11.5.2.1.2. Lateral Flow Assay

                11.5.2.1.3. PCR Assay

                11.5.2.1.4. ELISA Tests

                11.5.2.1.5. Culture Test

                11.5.2.1.6. Others

            11.5.2.2. Market Value Forecast, by Type, 2017–2031

                11.5.2.2.1. Syndromic Full Multiplex Panel

                11.5.2.2.2. Low Plex Panel

            11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                11.5.2.3.1. Hospitals

                11.5.2.3.2. Diagnostic Centers

                11.5.2.3.3. Others

        11.5.3. Rest of Middle East & Africa

            11.5.3.1. Market Value Forecast, by Product, 2017–2031

                11.5.3.1.1. Latex Agglutination Tests

                11.5.3.1.2. Lateral Flow Assay

                11.5.3.1.3. PCR Assay

                11.5.3.1.4. ELISA Tests

                11.5.3.1.5. Culture Test

                11.5.3.1.6. Others

            11.5.3.2. Market Value Forecast, by Type, 2017–2031

                11.5.3.2.1. Syndromic Full Multiplex Panel

                11.5.3.2.2. Low Plex Panel

            11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                11.5.3.3.1. Hospitals

                11.5.3.3.2. Diagnostic Centers

                11.5.3.3.3. Others

    11.6. Market Attractiveness Analysis

        11.6.1. By Product

        11.6.2. By Type

        11.6.3. By End-user

        11.6.4. By Country

12. Competition Landscape

    12.1. Company Profiles

        12.1.1. Thermo Fisher Scientific, Inc.

            12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.1.2. Product Portfolio

            12.1.1.3. SWOT Analysis

            12.1.1.4. Strategic Overview

        12.1.2. BioFire Diagnostics

            12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.2.2. Product Portfolio

            12.1.2.3. SWOT Analysis

            12.1.2.4. Strategic Overview

        12.1.3. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers

            12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.3.2. Product Portfolio

            12.1.3.3. SWOT Analysis

            12.1.3.4. Strategic Overview

        12.1.4. Bio-Rad Laboratories, Inc.

            12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.4.2. Product Portfolio

            12.1.4.3. SWOT Analysis

            12.1.4.4. Strategic Overview

        12.1.5. IMMY

            12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.5.2. Product Portfolio

            12.1.5.3. SWOT Analysis

            12.1.5.4. Strategic Overview

        12.1.6. Nanosphere (Luminex Corporation)

            12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.6.2. Product Portfolio

            12.1.6.3. SWOT Analysis

            12.1.6.4. Strategic Overview

        12.1.7. Seegene, Inc.

            12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.7.2. Product Portfolio

            12.1.7.3. SWOT Analysis

            12.1.7.4. Strategic Overview

        12.1.8. Qnostics

            12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.8.2. Product Portfolio

            12.1.8.3. SWOT Analysis

            12.1.8.4. Strategic Overview

        12.1.9. ELITechGroup

            12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.9.2. Product Portfolio

            12.1.9.3. SWOT Analysis

            12.1.9.4. Strategic Overview

        12.1.10. Abbott Laboratories

            12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.1.10.2. Product Portfolio

            12.1.10.3. SWOT Analysis

            12.1.10.4. Strategic Overview

        12.1.11. Other Prominent Players

List of Table

Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017–2031

Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figure

Figure 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Product Type (2020)

Figure 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by End-user (2020)

Figure 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Panel Type (2020)

Figure 05: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Region (2020)

Figure 06: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 07: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Latex Agglutination Tests, 2017–2031

Figure 08: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Lateral Flow Assay, 2017–2031

Figure 09: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by PCR Assay, 2017–2031

Figure 10: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by ELISA Tests, 2017–2031

Figure 11: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Culture Test, 2017–2031

Figure 12: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by others, 2017–2031

Figure 13: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 14: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 15: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

Figure 16: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Low Plex Panel, 2017–2031

Figure 17: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 18: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 19: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 20: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

Figure 21: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Others, 2017–2031

Figure 22: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 23: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Region, 2020 and 2031

Figure 24: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Region, 2021-2031

Figure 25: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 26: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 27: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 28: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 29: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-User, 2020 and 2031

Figure 30: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-User, 2021–2031

Figure 31: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Country, 2020 and 2031

Figure 32: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 34: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 35: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 36: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 37: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 38: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 39: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 40: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 41: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 42: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 43: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 44: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 45: France Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 46: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 47: France Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 48: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 49: France Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 50: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 51: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 52: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 53: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 54: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 55: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 56: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 57: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 58: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 59: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 60: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 61: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 62: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 64: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 65: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 66: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 67: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 68: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 69: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 70: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 71: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 72: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 73: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 74: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 75: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 76: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 77: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 78: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 79: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 80: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 81: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 82: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 83: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 84: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 85: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 86: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 87: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 88: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 89: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 90: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 91: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 92: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 93: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 94: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 95: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 96: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 97: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 98: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 99: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 100: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 101: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 102: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 103: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 104: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 105: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 106: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 107: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 108: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 109: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 110: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 111: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 112: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 113: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 114: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 115: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 116: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 117: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 118: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 119: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 120: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 121: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 122: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 123: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 124: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 125: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 126: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 127: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 128: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 129: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 130: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 131: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 132: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 133: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 134: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 135: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 136: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 137: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 138: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 139: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

Figure 140: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

Figure 141: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 142: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Meningitis Diagnostic Testing Market